Showing results (81-90 of 861) with videos related to
Sort By:
Pageof 87
Med (New York, N.Y.)|January 13, 2024
A systematic analysis of the landscape of synthetic lethality-driven precision oncologyAlejandro A Schäffer, Youngmin Chung, Ashwin V Kammula, et al.Med (New York, N.Y.)|January 13, 2024
Myocardial ischemia/reperfusion: Translational pathophysiology of ischemic heart diseaseGerd HeuschMed (New York, N.Y.)|December 21, 2023
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancerXiaolin Zhu, Vadim S KoshkinMed (New York, N.Y.)|March 26, 2024
Twin study dissects CXCR3+ memory B cells as non-heritable feature in multiple sclerosisFlorian Ingelfinger, Kirsten L Kuiper, Can Ulutekin, et al.Med (New York, N.Y.)|January 25, 2024
Isoform-selective TGF-β3 inhibition for systemic sclerosisTianhe Sun, Jason A Vander Heiden, Xia Gao, et al.Med (New York, N.Y.)|December 9, 2023
Safety concerns surrounding AAV and CRISPR therapies in neuromuscular treatmentHarry Wilton-Clark, Toshifumi YokotaMed (New York, N.Y.)|December 9, 2023
SURMOUNTing body weight barriers in type 2 diabetesAaron Novikoff, Timo D MüllerMed (New York, N.Y.)|November 11, 2023
Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?Mohamed A Gouda, Kyaw Z TheinMed (New York, N.Y.)|November 11, 2023
IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLCMiguel García-Pardo, Laura MezquitaMed (New York, N.Y.)|July 18, 2024
Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trialSuad Hannawi, Xiao-Hong Wu, Ralph Elvi Villalobos, et al.Pageof 87